The pharmaceutical science pertaining to the "collection, identification, assessment, monitoring, and prevention" of adverse effects with pharmaceutical goods is known as Pharmacovigilance (PV, or PhV), also known as drug safety. Pharmakon (Greek for drug) and vigilare are the etymological sources of the phrase "Pharmacovigilance" (Latin for to keep watch). Consequently, pharmacovigilance puts a lot of emphasis on adverse drug reactions (ADR), which are described as any reaction to a drug that is unpleasant and unintended, such as a lack of effectiveness (the condition that this definition only applies with the doses normally used for the prophylaxis, diagnosis or therapy of disease, or for the modification of physiological disorder function was excluded with the latest amendment of the applicable legislation). Even without an adverse event, medication mistakes such overdosing, drug addiction, misuse, and exposure to drugs when pregnant or nursing are of relevance because they may trigger an unfavourable pharmacological reaction.
Vladlen Slepak
University of Miami, United States
Axel H Schonthal
University of Southern California, United States
Bernd Blobel
University of Regensburg, Germany
Consolato M Sergi
University of Alberta, Canada
Luis Jesus Villarreal Gomez
Universidad Autónoma de Baja California, Mexico
Anil Pareek
Anand Pharmacy College, India
Saad Tayyab
UCSI University, Malaysia
Lan Wang
Paretor LLC, United States
Ravi P Sahu
Wright State University, United States
Bhasker Sambar
Alvogen Inc, United StatesSubmit your abstract Today
Title : Development of novel drug delivery pathways enabled by perillyl alcohol (NEO100), A monoterpene with multifaceted biomedical applications
Axel H Schonthal, University of Southern California, United States
Title : From marker to mechanism: Ligand discovery enables functional analysis of OR51E1, an ectopic olfactory receptor, in prostate cancer
Vladlen Slepak, University of Miami, United States
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, University of Alberta, Canada
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model based on design-inspired biotech- & biopharma-driven applications to secure the human healthcare and biosafety
Sergey Suchkov, N D Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : R&D consultancy at the medicines discovery catapult: De-risking drug discovery for innovators
Adriana Gambardella, Medicine Discovery Catapult, United Kingdom
Title : Biocompatible synthesis of non crystalline iron oxide nanoparticles with stable colloidal properties
Lan Wang, Paretor LLC, United States
Title : Precision diagnostics: Effectiveness of innovative imaging technologies for early detection of lung cancers
Huiqin Yang, ICON Clinical Research Ltd, United Kingdom
Title : Principles and standards for managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Design and characterization of gum arabic buccal films for protein drug delivery
Krisztian Pamlenyi, University of Szeged, Hungary
Title : Advancing EGFR-targeting macrocyclic peptide-drug conjugates to target KRAS-mutant solid tumors: Design, synthesis, and preclinical evaluations
Akash Panja, Ariel University, Israel